CNB Bank Cuts Position in Eli Lilly and Company $LLY

CNB Bank reduced its position in Eli Lilly and Company (NYSE:LLY) by 5.8% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,192 shares of the company’s stock after selling 74 shares during the period. CNB Bank’s holdings in Eli Lilly and Company were worth $929,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Hobbs Wealth Management LLC grew its position in shares of Eli Lilly and Company by 0.8% in the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company’s stock valued at $1,205,000 after purchasing an additional 12 shares during the last quarter. Hixon Zuercher LLC grew its holdings in Eli Lilly and Company by 0.7% during the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company’s stock valued at $1,477,000 after purchasing an additional 12 shares in the last quarter. O Brien Wealth Partners LLC grew its holdings in Eli Lilly and Company by 25.5% during the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock worth $49,000 after acquiring an additional 12 shares in the last quarter. Ascent Capital Management LLC grew its holdings in Eli Lilly and Company by 2.5% during the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company’s stock worth $409,000 after acquiring an additional 12 shares in the last quarter. Finally, Willner & Heller LLC grew its holdings in Eli Lilly and Company by 1.5% during the 1st quarter. Willner & Heller LLC now owns 854 shares of the company’s stock worth $705,000 after acquiring an additional 13 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.6%

LLY opened at $825.86 on Friday. The firm’s 50-day simple moving average is $768.01 and its 200-day simple moving average is $768.14. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63. The firm has a market cap of $781.65 billion, a price-to-earnings ratio of 53.98, a PEG ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director Jamere Jackson purchased 200 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the transaction, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Daniel Skovronsky purchased 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the transaction, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock worth $2,894,841 over the last quarter. Corporate insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on LLY shares. UBS Group cut their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Leerink Partnrs downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. HSBC boosted their price objective on shares of Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Friday. Finally, Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $938.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.